OBJECTIVE: CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels. We examined the effect of epidemiologic variables and tumor features on CA125 at diagnosis and their effects on survival. METHODS: CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded. CA125 values were log-normalized and generalized linear, logistic, or Cox proportional hazards models used to identify predictors of CA125 and influence on survival in the subset of women with invasive, nonmucinous tumors. RESULTS: The importance of histology, grade, stage, laterality, and presence of ascites on CA125 level was confirmed. For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125. A quadratic model best described the relationship between CA125 and age with lower levels in youngest and oldest women. In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125. A model with these variables plus CA125 revealed high CA125 remains a predictor of poorer survival. CONCLUSIONS: Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.
OBJECTIVE:CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels. We examined the effect of epidemiologic variables and tumor features on CA125 at diagnosis and their effects on survival. METHODS:CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded. CA125 values were log-normalized and generalized linear, logistic, or Cox proportional hazards models used to identify predictors of CA125 and influence on survival in the subset of women with invasive, nonmucinous tumors. RESULTS: The importance of histology, grade, stage, laterality, and presence of ascites on CA125 level was confirmed. For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125. A quadratic model best described the relationship between CA125 and age with lower levels in youngest and oldest women. In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125. A model with these variables plus CA125 revealed high CA125 remains a predictor of poorer survival. CONCLUSIONS:Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.
Authors: C Miralles; M Orea; P España; M Provencio; A Sánchez; B Cantos; R Cubedo; E Carcereny; F Bonilla; T Gea Journal: Ann Surg Oncol Date: 2003-03 Impact factor: 5.344
Authors: L A Hefler; A C Rosen; A H Graf; M Lahousen; M Klein; S Leodolter; A Reinthaller; C Kainz; C B Tempfer Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: Brian C Cooper; Anil K Sood; Charles S Davis; Justine M Ritchie; Joel I Sorosky; Barrie Anderson; Richard E Buller Journal: Obstet Gynecol Date: 2002-07 Impact factor: 7.661
Authors: R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp Journal: N Engl J Med Date: 1983-10-13 Impact factor: 91.245
Authors: M M Gourevitch; S von Mensdorff-Pouilly; S V Litvinov; P Kenemans; G J van Kamp; A A Verstraeten; J Hilgers Journal: Br J Cancer Date: 1995-10 Impact factor: 7.640
Authors: Benjamin A Katchman; Diego Chowell; Garrick Wallstrom; Allison F Vitonis; Joshua LaBaer; Daniel W Cramer; Karen S Anderson Journal: Gynecol Oncol Date: 2017-04-18 Impact factor: 5.482
Authors: Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer Journal: Gynecol Oncol Date: 2014-01-23 Impact factor: 5.482
Authors: Daniel W Cramer; Kristina Williams; Allison F Vitonis; Hidemi S Yamamoto; Alison Stuebe; William R Welch; Linda Titus; Raina N Fichorova Journal: Cancer Causes Control Date: 2013-08-08 Impact factor: 2.506
Authors: Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry Journal: Cancer Causes Control Date: 2017-01-03 Impact factor: 2.506
Authors: Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou Journal: Int J Gynecol Cancer Date: 2021-06-10 Impact factor: 3.437
Authors: Kristina A Williams; Kathryn L Terry; Shelley S Tworoger; Allison F Vitonis; Linda J Titus; Daniel W Cramer Journal: PLoS One Date: 2014-02-13 Impact factor: 3.240